Growth
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
Delivery percentage
Over the last 20 sessions KPL settled 42.7% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 46.6%, so recent sessions are running 3.9 points lower than usual.
What delivery percentage measuresScan the whole market on delivery
Dividends, deals & holders
Performance returns
| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -3.69% | +8.00% | +14.10% | +13.72% | +97.82% | — |
Valuation
Ownership
52-week highs & lows
Each session the stock traded past its previous 52-week high or low, from NSE's daily report; the previous figure is the record it broke. Prices as published, not split-adjusted.
Price-band hits
Sessions the stock closed at the limit of its daily price band, from NSE's end-of-day list. A stock pinned at the band could not trade past it that day.
Short selling, lending & margin
Shares bought on broker margin funding (MTF) and still held at the day’s end, and the amount brokers have lent against them.
Exchange surveillance
- Price move > 100% in 1 year · since 20 Nov 2026 — One of the criteria NSE’s surveillance watches: price move > 100% in 1 year.
- Price move > 75% in 6 months · since 15 Sept 2026 — One of the criteria NSE’s surveillance watches: price move > 75% in 6 months.
- High-low range > 100% in 6 months · since 15 Sept 2026 — One of the criteria NSE’s surveillance watches: high-low range > 100% in 6 months.
Price band: 20% · not in the F&O ban.
From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures.
Every stock on this session →KPL at a glance
- KPL closed at ₹4,128.4 on 20 Nov 2026, -3.69% on the day.
- Delivery was 38.2% of traded quantity on 20 Nov 2026, the 17th percentile of its own 149 sessions with a reading (20-session average 42.7%, 1-year average 46.6%).
- Market capitalisation is ₹4,284 crore, with no positive trailing earnings for a P/E.
About
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.
More in Pharmaceuticals & Biotechnology
- DIDIVISLABDivi's Laboratories Limited11,180.50+0.02%
- LALAURUSLABSLaurus Labs Limited2,294.60-0.49%
- SUSUNPHARMASun Pharmaceutical Industries Limited1,884.90-0.79%
- ACACUTAASAcutaas Chemicals Limited3,833.50-3.61%
- SASAILIFESai Life Sciences Limited1,800.70+0.69%
- PPPPLPHARMAPiramal Pharma Limited239.30-0.15%
- DRDRREDDYDr. Reddy's Laboratories Limited1,390.20-0.76%
- GLGLENMARKGlenmark Pharmaceuticals Limited2,648.00+1.51%
- AUAUROPHARMAAurobindo Pharma Limited1,799.00-0.37%
- CICIPLACipla Limited1,415.00-0.25%
- ZYZYDUSLIFEZydus Lifesciences Limited1,200.00-0.24%
- MAMANKINDMankind Pharma Limited2,665.00+1.37%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE